This study reveals the significant efficacy of a PD-1/CTLA-4 bispecific antibody combined with Lenvatinib in the second-line treatment of endometrial cancer and confirms that dynamic ctDNA monitoring serves as a key biomarker for predicting PFS and OS, providing direct evidence for optimizing immunotherapy strategies.
Literature Overview
The article titled "Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial," published in Nature Communications, systematically explores the antitumor activity, safety, and predictive value of ctDNA dynamics of the bispecific antibody Cadonilimab combined with Lenvatinib as a second-line or subsequent therapy for patients with advanced endometrial cancer who have progressed after platinum-based chemotherapy.Background Knowledge
1. The pain point addressed by this study in endometrial cancer is that, although first-line immunotherapy combined with chemotherapy has been approved, there is a lack of highly effective and well-tolerated second-line treatment options after disease progression, particularly for patients with the pMMR subtype who have a very poor prognosis. 2. Current research bottlenecks in PD-1 and CTLA-4 pathway inhibitors include limited efficacy of monotherapy and reduced clinical compliance due to high-dose toxicity when combined with TKIs (such as Lenvatinib), alongside a lack of liquid biopsy biomarkers capable of early prediction of efficacy and resistance mechanisms. 3. The entry point of this study lies in evaluating the synergistic effect of Cadonilimab (PD-1/CTLA-4 bispecific antibody) with a low dose of Lenvatinib, and introducing dynamic ctDNA monitoring to analyze the correlation between treatment response and mutations in genes such as TP53 and PIK3CA.
Research Methods and Core Experiments
The authors conducted a multicenter, single-arm Phase II clinical trial (CLEAR-EC). First, a safety run-in period involving 3 patients determined the Recommended Phase 2 Dose (RP2D) of Lenvatinib 16 mg/day combined with Cadonilimab 10 mg/kg. Subsequently, 29 patients were enrolled for efficacy evaluation. Tumor response was assessed using RECIST 1.1 criteria. Plasma samples were collected at baseline, on Day 1 of Cycle 3 (C3D1), and at disease progression. Deep sequencing was performed using a 437-gene panel for ctDNA, combined with mutational profile analysis of key genes such as TP53, PIK3CA, and PTEN to analyze treatment response and resistance mechanisms.Key Conclusions and Perspectives
Research Significance and Prospects
These findings are significant for drug development, demonstrating that reducing the starting dose of Lenvatinib (16 mg) significantly improves safety while maintaining efficacy, providing an optimized dosing regimen for clinical practice. In terms of clinical monitoring, the study establishes the feasibility of dynamic ctDNA as an early warning tool, facilitating timely adjustment of treatment strategies. Furthermore, the study reveals genomic characteristics such as co-mutations in TP53 and PIK3CA, providing theoretical support for future construction of more precise disease models and targeted combination therapies.
Conclusion
The CLEAR-EC trial confirms that Cadonilimab combined with Lenvatinib is a highly promising second-line treatment option for patients with advanced endometrial cancer who have progressed after platinum-based therapy, significantly improving patient prognosis with high ORR and long PFS. The study not only validates the clinical value of combining bispecific antibodies with TKIs in pMMR tumors but also, through dynamic ctDNA monitoring technology, provides actionable biomarkers for precisely identifying beneficiaries and early warning of resistance. From laboratory to clinical translation, this study emphasizes the core role of molecular subtyping and liquid biopsy in optimizing immunotherapy decisions, laying a solid foundation for building a personalized whole-course management system for endometrial cancer, and is expected to become an important treatment paradigm recommended in future guidelines.
